HSD8 Real-World Patient Persistence: A Comparison of Prostaglandin Analogs Used for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
This study aims to compare persistence on latanoprostene bunod, latanoprost, bimatoprost, travoprost, and Beta Blockers, within a 12-month analysis period. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: C Laforty, S Feener, P Grover, A Sharma, M Barbeau Source Type: research
Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension
CONCLUSIONS: The current evidence suggests that in people diagnosed with OHT or (P)OAG, the hypotensive effect of netarsudil may be inferior to latanoprost and slightly inferior to timolol. Combining netarsudil and latanoprost probably further reduces IOP compared with monotherapy. Netarsudil as mono- or combination therapy may result in more ocular AEs. However, the certainty of evidence was very low or low for all comparisons except timolol. In general, AEs were described as mild, transient, and reversible upon treatment discontinuation. ROKi was not associated with any particular serious AEs. Future trials of sufficient...
Source: Cochrane Database of Systematic Reviews - June 10, 2022 Category: General Medicine Authors: Josefine Clement Freiberg Alexander von Spreckelsen Miriam Kolko Augusto Azuara-Blanco Gianni Virgili Source Type: research
Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension
CONCLUSIONS: The current evidence suggests that in people diagnosed with OHT or (P)OAG, the hypotensive effect of netarsudil may be inferior to latanoprost and slightly inferior to timolol. Combining netarsudil and latanoprost probably further reduces IOP compared with monotherapy. Netarsudil as mono- or combination therapy may result in more ocular AEs. However, the certainty of evidence was very low or low for all comparisons except timolol. In general, AEs were described as mild, transient, and reversible upon treatment discontinuation. ROKi was not associated with any particular serious AEs. Future trials of sufficient...
Source: Cochrane Database of Systematic Reviews - June 10, 2022 Category: General Medicine Authors: Josefine Clement Freiberg Alexander von Spreckelsen Miriam Kolko Augusto Azuara-Blanco Gianni Virgili Source Type: research
Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension
CONCLUSIONS: The current evidence suggests that in people diagnosed with OHT or (P)OAG, the hypotensive effect of netarsudil may be inferior to latanoprost and slightly inferior to timolol. Combining netarsudil and latanoprost probably further reduces IOP compared with monotherapy. Netarsudil as mono- or combination therapy may result in more ocular AEs. However, the certainty of evidence was very low or low for all comparisons except timolol. In general, AEs were described as mild, transient, and reversible upon treatment discontinuation. ROKi was not associated with any particular serious AEs. Future trials of sufficient...
Source: Cochrane Database of Systematic Reviews - June 10, 2022 Category: General Medicine Authors: Josefine Clement Freiberg Alexander von Spreckelsen Miriam Kolko Augusto Azuara-Blanco Gianni Virgili Source Type: research
A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study
Conclusions:
NCX 470 demonstrated dose-dependent reductions in IOP. The 0.042% and 0.065% concentrations demonstrated significantly greater reductions from baseline in mean diurnal IOP than latanoprost 0.005% at week 4, suggesting that higher concentrations may show even greater efficacy. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - June 1, 2022 Category: Opthalmology Tags: New Glaucoma Insights: Original Studies Source Type: research
Brinzolamide- and latanoprost-loaded nano lipid carrier prevents synergistic retinal damage in glaucoma
Acta Biochim Pol. 2022 May 26. doi: 10.18388/abp.2020_5885. Online ahead of print.ABSTRACTGlaucoma is a common eye disease and a major cause of blindness. We designed brinzolamide (Brla)- and latanoprost (Ltp)-loaded nano-lipoidal carriers (NLCs) for glaucoma treatment. Brla and Ltp-loaded NLCs were designed and characterized by assessing the zeta potential, polydispersity index, X-ray diffraction and scanning electron microscopy images, and particle size. Drug release was assessed by in vitro and ex vivo methods to determine transcorneal permeation, ocular irritation, and cell viability. Moreover, Brla- and Ltp-loaded NLC...
Source: Acta Biochim Pol - May 26, 2022 Category: Biochemistry Authors: Liping Chen Ruixin Wu Source Type: research
Brinzolamide- and latanoprost-loaded nano lipid carrier prevents synergistic retinal damage in glaucoma
Acta Biochim Pol. 2022 May 26. doi: 10.18388/abp.2020_5885. Online ahead of print.ABSTRACTGlaucoma is a common eye disease and a major cause of blindness. We designed brinzolamide (Brla)- and latanoprost (Ltp)-loaded nano-lipoidal carriers (NLCs) for glaucoma treatment. Brla and Ltp-loaded NLCs were designed and characterized by assessing the zeta potential, polydispersity index, X-ray diffraction and scanning electron microscopy images, and particle size. Drug release was assessed by in vitro and ex vivo methods to determine transcorneal permeation, ocular irritation, and cell viability. Moreover, Brla- and Ltp-loaded NLC...
Source: Acta Biochim Pol - May 26, 2022 Category: Biochemistry Authors: Liping Chen Ruixin Wu Source Type: research
Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France
CONCLUSION: Once on the market, STN1013001 will provide the French health system with a cost-effective treatment versus Latanoprost for OAG/OHT + OSD patients. These results should be confirmed by future economic evaluations carried out alongside empirical trials.PMID:35529166 | PMC:PMC9076337 | DOI:10.1155/2022/3837471 (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - May 9, 2022 Category: Opthalmology Authors: Carlo Lazzaro C écile van Steen Florent Aptel C édric Schweitzer Luigi Angelillo Source Type: research
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
CONCLUSION: PF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively.CLINICAL STUDY NUMBER: European Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204.PMID:35524840 | DOI:10.1007/s12325-022-02166-6 (Source: Adv Data)
Source: Adv Data - May 7, 2022 Category: Epidemiology Authors: Francesco Oddone James Kirwan Fernando Lopez-Lopez Marina Zimina Claudia Fassari G ábor Holló VISIONARY Study Group Source Type: research
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
CONCLUSION: PF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively.CLINICAL STUDY NUMBER: European Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204.PMID:35524840 | DOI:10.1007/s12325-022-02166-6 (Source: Adv Data)
Source: Adv Data - May 7, 2022 Category: Epidemiology Authors: Francesco Oddone James Kirwan Fernando Lopez-Lopez Marina Zimina Claudia Fassari G ábor Holló VISIONARY Study Group Source Type: research
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
ConclusionPF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively.Clinical Study NumberEuropean Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204. (Source: Advances in Therapy)
Source: Advances in Therapy - May 7, 2022 Category: Drugs & Pharmacology Source Type: research
